Welcome to our dedicated page for Renovorx SEC filings (Ticker: RNXT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sorting through a clinical-stage company’s disclosures can feel like decoding medical literature. Renovorx’s 10-K and 10-Q filings weave together TAMP platform data, FDA designations, and cash-runway assumptions—details investors can’t afford to miss. That’s why this page opens every Renovorx insider trading Form 4 transactions record and each Renovorx quarterly earnings report 10-Q filing the moment EDGAR releases them.
Stock Titan’s AI reads the dense language for you, turning hundreds of pages into concise explanations. Need to spot pipeline milestones? Our platform links section references inside the Renovorx annual report 10-K simplified. Curious about sudden leadership moves? Renovorx Form 4 insider transactions real-time alerts flag executive buys and sells as they post. Looking for board pay practices? The Renovorx proxy statement executive compensation data is summarized next to benchmark peers. We even deliver Renovorx 8-K material events explained within minutes, so surprises never stay hidden.
Use the tools professionals rely on:
- AI-powered highlights that make understanding Renovorx SEC documents with AI straightforward.
- Side-by-side Renovorx earnings report filing analysis to track trial expenses versus cash reserves.
- Instant notifications of Renovorx executive stock transactions Form 4 before market open.
AWM Investment Company, Inc. reports beneficial ownership of 1,870,225 shares of RenovoRx common stock, representing 5.1% of the class. AWM is the investment adviser to three funds that together hold the shares and, as adviser, holds sole voting and dispositive power over the position. The reported holdings break down to 1,064,431 shares held by Special Situations Fund III QP, 296,698 shares held by Special Situations Cayman Fund, and 509,096 shares held by Special Situations Life Sciences Fund.
The filing includes a certification that the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer.
RenovoRx, Inc. (Nasdaq: RNXT) filed a Form 8-K to report the voting results of its 2025 Annual Meeting held on 24 June 2025. Of the 36,551,752 shares outstanding on the 25 April 2025 record date, approximately 20,086,518 shares (55%) were present or represented by proxy, satisfying quorum requirements.
Proposal 1 – Director Elections: All seven nominees were elected to one-year terms expiring at the 2026 meeting. Four directors (Bagai, Agah, Macfarlane) received ~13.0 million votes each with minimal withholds, while three directors (Marton, Ryan, Spiegel) received ~9.5-9.9 million votes and ~3.3-3.6 million withholds. Broker non-votes were 6.95 million for every nominee.
Proposal 2 – Equity Incentive Plan Amendments: Shareholders approved (i) reserving an additional 913,794 shares (2.5% of outstanding) for the 2021 Omnibus Equity Incentive Plan and (ii) raising the plan’s evergreen provision from 3% to 5% of year-end shares. Votes: 9,056,181 for; 4,037,698 against; 38,379 abstentions; 6,954,260 broker non-votes.
Proposal 3 – Auditor Ratification: Frank, Rimerman + Co. LLP was ratified as independent auditor for FY 2025 with strong support (19,131,750 for; 949,070 against; 5,698 abstentions).
The filing discloses no financial performance metrics or strategic transactions but confirms routine corporate governance matters, an expanded share reserve for equity compensation, and continuity of external audit oversight.
FAQ
What is the current stock price of Renovorx (RNXT)?
What is the market cap of Renovorx (RNXT)?
